Eribulin as First-Line Therapy for Metastatic HER2-Negative Breast Cancer
Joyce A. O’Shaughnessy, MD, from Baylor Charles A. Sammons Cancer Center, discusses the results of a recent breast cancer study.
Clinical Pearls
Joyce A. O’Shaughnessy, MD, the Co-Director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center; Texas Oncology, PA/US Oncology, Dallas, Texas, discusses the results of a recent breast cancer study.
- This study looked at eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.
- Overall response rate was 29%.
- Clinical benefit rate was 52%.
- Median PFS was 6.8 months.
- Responses were seen regardless of ER status.
Recent Videos
Related Content
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024Article
During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
